Med spas order compounded medications for two different jobs. Some go home with a patient: a weight-management prescription, a topical formula, a peptide. Others are administered on site, as an injection given during a visit. Federal law treats those two jobs differently, and many compliance problems in a med spa start with ordering one the way the other should be ordered.
This guide sets out the two pathways, what each asks of a med spa, and how ordering works on ScriptLinkRx. Scope of practice, supervision and examination rules are set by each state and are not covered here. Confirm them with your medical board and board of pharmacy.
Two pathways, by service
| What the med spa does | Pathway | What it takes |
|---|---|---|
| Sends a patient home with a compounded medication | 503A | A prescription written by a licensed prescriber for that patient, filled by a pharmacy licensed in the patient's state |
| Administers a compounded injection during a visit, from stock | 503B | Enrollment with an FDA-registered outsourcing facility, in a state that permits office-use purchasing |
A 503A pharmacy cannot fill an order "for the spa." Under federal law it compounds on a prescription for an identified patient, so stock for the treatment room has to come from a 503B outsourcing facility. The 503A vs 503B guide explains the difference in full.
What med spas order
In ScriptLinkRx's 2026 ranking of the most-prescribed compounded medications, med spa ordering is concentrated in GLP-1 combinations, longevity and wellness compounds, and recovery peptides. Each category has its own regulatory picture:
- GLP-1s are the most scrutinized category in compounding. Semaglutide and tirzepatide are off the shortage list, 503B facilities cannot compound them under current rules, and a 503A pharmacy may prepare them only where the prescriber documents a significant difference for the individual patient. Read the GLP-1 sourcing guide before building a program on them.
- Peptides depend on whether the substance may lawfully be used in compounding. The July 2026 advisory committee votes moved BPC-157 and TB-500 closer to a lawful pathway, but no final listing had been published as of October 2026. See the peptide sourcing guide.
- NAD+ and glutathione are compounded as injectables, where ingredient grade and sterility are the main quality questions. See the provider guides to NAD+ and glutathione.
- Topical and aesthetic formulations such as GHK-Cu are prescribed for individual patients and follow the 503A pathway.
The prescriber stays in charge
Every patient-specific order on ScriptLinkRx is a prescription written and signed by a licensed prescriber for an identified patient. For a med spa that has three consequences:
- Someone with prescriptive authority has to evaluate the patient. Who may do that, whether the examination can be delegated or done by telehealth, and what a medical director must supervise are questions of state law. The platform records the prescriber on each order; it does not decide who may prescribe in your state.
- No menus of pre-selected formulations. The FDA's September 2026 warning letter to a large compounder criticized templated justifications and third-party platforms that offer prescribers pre-selected options. On ScriptLinkRx the prescriber chooses the product, enters directions and clinical notes for that patient, and signs.
- Claims to patients need care. Compounded medications are not FDA-approved and should not be presented as generic or equivalent versions of an approved brand.
Office stock for the treatment room
For product administered on site, a med spa orders office-use stock from a 503B outsourcing facility:
- Enroll with the facility. The enrollment form is completed inside ScriptLinkRx. Each facility verifies the practice and the ordering prescriber before it ships.
- Order from the office-use catalog. Once the facility approves the enrollment, its catalog opens. The order ships to the practice, not to a patient.
- Administer and record. Each administration is documented in the patient's chart. Office stock is not dispensed for patients to take home.
Whether your med spa may purchase office-use compounded products, in what quantities, and who may administer them depends on your state. Controlled substances add a DEA registration and storage requirements. The 503B office-use guide lists the records a practice should keep.
What one platform changes
- One catalog across pharmacies. The catalog shows products from partner pharmacies that can ship to the selected patient's state, with each pharmacy's price before checkout. A med spa with locations in several states does not keep a licensing spreadsheet.
- Clinic-pay or patient-pay. The med spa can pay and bill the patient itself, or send the patient a secure payment link.
- Tracking without phone calls. Orders move through pharmacy review, compounding and shipment in one list, and patients receive tracking once the pharmacy ships.
- Separate checkouts for 503A and 503B. Patient prescriptions and office-stock orders never share a cart.
- Records in one place. Order history, receipts and prescription records are kept per patient and per business.
Sources
- FDA: FD&C Act Provisions that Apply to Human Drug Compounding (sections 503A and 503B)
- FDA: Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act (guidance)
- FDA: Registered Outsourcing Facilities
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (April 2026)
- FDA: Warning Letters (search "Empower Clinic Services", September 18, 2026)